PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Tumor-infiltrating myeloid cells such as myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) form an important component of the hypoxic tumor microenvironment. Here, we investigated the influence of hypoxia on immune checkpoint receptors (programmed death [PD]-1 and CTLA-4) and their respective ligands (PD-1 ligand 1 [PD-L1], PD-L2, CD80, and CD86) on MDSCs. We demonstrate that MDSCs at the tumor site show a differential expression of PD-L1 as compared with MDSCs from peripheral lymphoid organ (spleen). Hypoxia caused a rapid, dramatic, and selective up-regulation of PD-L1 on splenic MDSCs in tumor-bearing mice. This was not limited to MDSCs, as hypoxia also significantly increased the expression of PD-L1 on macrophages, dendritic cells, and tumor cells. Furthermore, PD-L1 up-regulation under hypoxia was dependent on hypoxia-inducible factor-1α (HIF-1α) but not HIF-2α. Chromatin immunoprecipitation and luciferase reporter assay revealed direct binding of HIF-1α to a transcriptionally active hypoxia-response element (HRE) in the PD-L1 proximal promoter. Blockade of PD-L1 under hypoxia enhanced MDSC-mediated T cell activation and was accompanied by the down-regulation of MDSCs IL-6 and IL-10. Finally, neutralizing antibodies against IL-10 under hypoxia significantly abrogated the suppressive activity of MDSCs. Simultaneous blockade of PD-L1 along with inhibition of HIF-1α may thus represent a novel approach for cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4. Blockade of PD-L1 under hypoxia down-regulates MDSC IL-6 and IL-10 and enhances T cell proliferation and function. MDSCs isolated from spleens of B16-F10 tumor-bearing mice were pretreated for 30 min on ice with 5 µg/ml control antibody (IgG) or antibody against PD-L1 (PDL1 Block) and co-cultured with splenocytes under normoxia and hypoxia for 72 h. (A and B) Effect of MDSC on proliferation of splenocytes stimulated with (A) anti-CD3/CD28 coated beads or (B) TRP-2(180–88) peptide under the indicated conditions. Cell proliferation was measured in triplicates by [3H]thymidine incorporation and expressed as counts per minute (CPM). (C and D) MDSCs were cultured with splenocytes from B16-F10 mice stimulated with anti-CD3/CD28. Intracellular IFN-γ production was evaluated by flow cytometry by gating on (C) CD3+CD8+ IFN-γ+ and (D) CD3+CD4+ IFN-γ+ populations. Statistically significant differences (indicated by asterisks) are shown (**, P < 0.005; ***, P < 0.0005). Three separate experiments (in triplicates) with the same results were performed. Error bars indicate SD. (E) SYBR-GREEN RT-qPCR was performed to evaluate the mRNA expression levels of Ldha, Car-9, Arg-1, Nos2, Ncf-1, and Cybb-1. (F) Arginase enzymatic activity measured in MDSCs under indicated conditions. (G) After 72 h of MDSC co-culture with splenocytes, supernatants were collected and assayed for nitrites. Data represents three independent experiments with SD. (H) SYBR Green RT-qPCR was performed for expression levels of IL6, IL10, Il12p70, and Tgfb1 under the indicated conditions. IL-6, IL-10, IL-12p70, and TGF-β1 cytokine production and secretion was detected by (I and J) intracellular FACS staining (isotype control is gray-shaded histogram) and (K) ELISA, respectively. Statistically significant differences (indicated by asterisks) are shown (*, P < 0.05; **, P < 0.005; ***, P < 0.0005). The experiment was performed in triplicates and repeated three times with the same results. Error bars indicate SD. (L–O) MDSCs isolated from spleens of B16-F10 tumor-bearing mice were co-cultured with splenocytes under normoxia and hypoxia for 72 h in the presence of either 10 µg/ml control antibody (IgG), anti–mouse IL-6 Functional Grade Purified neutralizing antibody (IL-6 Block) or anti–mouse IL-10 Functional Grade Purified neutralizing antibody (IL-10 Block). Effect of MDSCs on proliferation of splenocytes stimulated with (L) anti-CD3/CD28–coated beads or (M) TRP-2(180–88) peptide under the indicated conditions. Cell proliferation was measured as indicated above. MDSCs were cultured with splenocytes from B16-F10 mice stimulated with anti-CD3/CD28. Intracellular IFN-γ production was evaluated by flow cytometry by gating on (N) CD3+CD8+ IFN-γ+ and (O) CD3+CD4+ IFN-γ+ populations. Statistically significant differences (indicated by asterisks) are shown (*, P < 0.05; **, P < 0.005). Two separate experiments (in triplicates) with the same results were performed. Error bars indicate SD.](https://figures.cochat.ai/paper-figures/2ba8a156b22c410c8802e99a6f19ff08/pd-l1-is-a-novel-direct-target-of-hif-1-and-its-blockade-under-hypoxia-enhanced-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intriguingly, HIF-1α, but not HIF-2α, directly upregulates the expression of PD-L1 in macrophages, dendritic cells and bone marrow derived macrophages (BMDMs), by binding HREs within the PD-L1 promoter (Fig. 2C) [68–70].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [68]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As seen for the other cancer axes, the HIF-α dependency of PD-L1 is tumor-type dependent, with PD-L1 expression primarily HIF-1α driven in HIF-1α-dominant cancers (such as CT26 colon carcinoma and 4T1 breast carcinoma models) and HIF-2α-driven in HIF-2α-dominant cancers (ccRCC) [81, 83].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to regulating components of the innate immune response, the HIFs have been linked to modulation of the adaptive immune response through upregulation of both co-inhibitory (eg. PD-L1 and CTLA4) and co-stimulatory receptors (eg. 4–1BB, OX40) on activated T cells [80, 81].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent data indicate that hypoxia is also able to upregulate expression of PD-L1 in malignant cells via HIF-1α and HIF-2α (17).”
From Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy (2022) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Targeting HIF-1α in immunotherapy is a relatively new concept, for which proof of principle has been amply demonstrated by others (12, 23, 27).”
From Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues (2022) · cites this paper as [12]
Experimental — accuracy not yet measured
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“A large body of preclinical and clinical data indicates that antibody blockade of immune checkpoints can significantly enhance antitumor immunity (Pardoll, 2012; West et al., 2013).”
BackgroundSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 2×
“, 2012) and its ligand, PD-L1 (Brahmer et al., 2012), was shown to result in durable tumor regression and prolonged stabilization of disease in patients with advanced cancers.”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“MDSCs are a heterogeneous group of relatively immature myeloid cells and several studies have described mechanisms of MDSCmediated immune suppression (Gabrilovich et al., 2012).”
BackgroundSelf-citationGreenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318 · cited 1×
“PD-1, a cell surface glycoprotein with a structure similar to cytotoxic T lymphocyte antigen 4 (CTLA-4), belongs to the B7 family of co-stimulatory/co-inhibitory molecules and plays a key part in immune regulation (Greenwald et al., 2005).”
BackgroundSubsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645 · cited 3×
“It is important to underline that our results are in complete agreement with previous findings by Youn et al. (2008), indicating that normoxic blockade of PD-L1 did not eliminate suppressive activity of MDSCs.”
BackgroundMethodResultInfluentialBlockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314 · cited 12×
“2 I) and DCs (CD11c+; Fig.”
BackgroundResultInfluentialPD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173 · cited 6×
“As shown previously by Corzo et al. (2010), we observed higher levels of Arg-1 gene expression (Fig.”
BackgroundInfluentialOxygen Sensing, Homeostasis, and Disease
Semenza, G. L. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011165 · Cited by 993 · cited 1×
“2014 Vol. 211 No. 5 781-790 www.jem.org/cgi/doi/10.1084/jem.20131916 781 Brief Definit ive Report Hypoxia is a common feature of solid tumors (Semenza, 2011).”
BackgroundInfluential
Cited by
Items 201–300 of 1,009
Nicolini, A., & Ferrari, P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1353787 · Cited by 182
Szebeni, G. J., Vizler, C., Kitajka, K., & Puskas, L. G. (2017) · Mediators of Inflammation · doi:10.1155/2017/9294018 · Cited by 184
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation
Kandalaft, L. E., Dangaj Laniti, D., & Coukos, G. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00503-z · Cited by 180
The tumor microenvironment’s role in the response to immune checkpoint blockade
Aliazis, K., Christofides, A., Shah, R., Yeo, Y. Y., Jiang, S., Charest, A., & Boussiotis, V. A. (2025) · Nature Cancer · doi:10.1038/s43018-025-00986-3 · Cited by 178
“These include high expression of PD-L1, which, in tumor-infiltrating MDSCs, is regulated by the COX2–mPGES1–PGE 2 pathway, the pSTAT1–IRF1 axis and hypoxia-induced HIF-1α 53–55 .”
MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype
Sodir, N. M., Kortlever, R. M., Barthet, V. J. A., Campos, T., Pellegrinet, L., Kupczak, S., Anastasiou, P., Swigart, L. B., Soucek, L., Arends, M. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0435 · Cited by 182
Hypoxia-inducible factors and innate immunity in liver cancer
Yuen, V. W.-H., & Wong, C. C.-L. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137553 · Cited by 183
Hypoxia Compromises Anti-Cancer Immune Responses
Multhoff, G., & Vaupel, P. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-34461-0_18 · Cited by 181
Shin, S.-J., Jeon, Y. K., Kim, P.-J., Cho, Y. M., Koh, J., Chung, D. H., & Go, H. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4903-7 · Cited by 180
“bind to a transcriptionally active hypoxia-response element in the PD-L1 promoter and induce immune escape from cytotoxic T-cells under hypoxia.(29,30) Thus, a blockade of PD-L1 along with inhibition of VHL-HIF-VEGF pathway may represent a rational approach in advanced CCRCC.”
Glucose represses dendritic cell-induced T cell responses
Lawless, S. J., Kedia-Mehta, N., Walls, J. F., McGarrigle, R., Convery, O., Sinclair, L. V., Navarro, M. N., Murray, J., & Finlay, D. K. (2017) · Nature Communications · doi:10.1038/ncomms15620 · Cited by 181
Hypoxia-induced epithelial to mesenchymal transition in cancer
Hapke, R. Y., & Haake, S. M. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.012 · Cited by 178
“TAM, MDSC, DC, and cancer cells) in the hypoxic TME upregulate PD-L1 levels, diminishing the antitumor immune response[151].”
BackgroundWNT signaling and cancer stemness
Katoh, M., & Katoh, M. (2022) · Essays in Biochemistry · doi:10.1042/ebc20220016 · Cited by 179
Li, L., Cao, B., Liang, X., Lu, S., Luo, H., Wang, Z., Wang, S., Jiang, J., Lang, J., & Zhu, G. (2019) · Oncogene · doi:10.1038/s41388-018-0627-z · Cited by 179
Hypoxia and HIF Signaling: One Axis with Divergent Effects
Corrado, C., & Fontana, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165611 · Cited by 179
“Moreover, HIF1-α works as a direct inducer of PD-L1 (Programmed Death-Ligand 1) expression in cancer cells, macrophages, dendritic cells, and MDSCs, resulting in further effector T-cell inhibition and enhancing tumor immune escape [71,72].”
BackgroundHypoxia: The Cornerstone of Glioblastoma
Domènech, M., Hernández, A., Plaja, A., Martínez-Balibrea, E., & Balañà, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212608 · Cited by 173
PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma
Ruf, M., Moch, H., & Schraml, P. (2016) · International Journal of Cancer · doi:10.1002/ijc.30077 · Cited by 179
“In breast and prostate cancer cell lines hypoxia seems to be critical for PD-L1’s upregulation.(18,28) Notably, PD-L1 is the only member of the B7 family of immune-regulatory ligands, which could be stimulated by hypoxia.”
BackgroundTumor immune microenvironment in head and neck cancers
Chen, S. M. Y., Krinsky, A. L., Woolaver, R. A., Wang, X., Chen, Z., & Wang, J. H. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23162 · Cited by 179
“A recent study has discovered that tumor‐associated hypoxia caused an increase of PD‐L1 expression on tumor‐infiltrating MDSCs.(94) This upregulation of PD‐L1 on MDSCs was due to the transcription factor, hypoxia‐inducible factor 1‐α (HIF‐1α), which resulted in more potent immunosuppressive effects of MDSCs.”
BackgroundInfluentialIncreased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma
Du, Z., Abedalthagafi, M., Aizer, A. A., McHenry, A. R., Sun, H. H., Bray, M.-A., Viramontes, O., Machaidze, R., Brastianos, P. K., Reardon, D. A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3082 · Cited by 179
He, Q., Liu, M., Huang, W., Chen, X., Zhang, B., Zhang, T., Wang, Y., Liu, D., Xie, M., Ji, X., et al. (2021) · Hepatology · doi:10.1002/hep.32062 · Cited by 177
“SlC7a11 Up- RegUlateS pD- l1 eXpReSSIoN tHRoUgH tHe αKg- HIF1α patHWay Because HIF1α is a key positive regulator of PDL1 expression,(19,20) we set out to explore whether FIg.”
BackgroundMetabolic programming in dendritic cells tailors immune responses and homeostasis
Møller, S. H., Wang, L., & Ho, P.-C. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00753-1 · Cited by 169
Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity
Martin, J. D., Fukumura, D., Duda, D. G., Boucher, Y., & Jain, R. K. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a027094 · Cited by 175
“Under hypoxic conditions, myeloid-derived suppressor cells, macrophages, dendritic cells, and tumor cells express higher levels of immune checkpoint ligands (PD-L1) (Noman et al. 2014), which is one of several mechanisms through which hypoxia inhibits the cytolytic activity of T cells and other immune cell types (Doed…”
BackgroundInfluentialNeutrophils in Cancer immunotherapy: friends or foes?
Huang, X., Nepovimova, E., Adam, V., Sivak, L., Heger, Z., Valko, M., Wu, Q., & Kuca, K. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02004-z · Cited by 172
“[ 74 ] B u r k i tt l y m p h o m a , b r e a s t c a n c e r , c o l o n a d e n o c a r c i n o m a , a n d r e n a l c a r c i n o m a R a j i , S K - BR - 3 , D L D - 1 , L S - 174 T , H T - 29 , H C T - 116 , C a k i - 1 , R CC 4 , R CC 10 , a n d T K 10 c e ll l i n e s a n d S R G m i c e C…”
BackgroundPalsson-McDermott, E. M., Dyck, L., Zasłona, Z., Menon, D., McGettrick, A. F., Mills, K. H. G., & O’Neill, L. A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01300 · Cited by 173
Altered cancer metabolism in mechanisms of immunotherapy resistance
Ramapriyan, R., Caetano, M. S., Barsoumian, H. B., Mafra, A. C. P., Zambalde, E. P., Menon, H., Tsouko, E., Welsh, J. W., & Cortez, M. A. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.004 · Cited by 170
“HIF-1α has been reported to drive the expression of PDL1 on both MDSCs and tumor cells, resulting in immune suppression (Noman et al., 2014).”
BackgroundTumor hypoxia and radiotherapy: A major driver of resistance even for novel radiotherapy modalities
Beckers, C., Pruschy, M., & Vetrugno, I. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.11.006 · Cited by 167
Zheng, S., Wang, W., Shen, L., Yao, Y., Xia, W., & Ni, C. (2024) · Experimental Hematology & Oncology · doi:10.1186/s40164-024-00543-1 · Cited by 163
Jiang, H., Gebhardt, C., Umansky, L., Beckhove, P., Schulze, T. J., Utikal, J., & Umansky, V. (2015) · International Journal of Cancer · doi:10.1002/ijc.29297 · Cited by 169
“To address this question, we analyzed the expression of programmed death ligand-1 (PD-L1), which has been reported to play an important role in the function of these cells.(7,31,32) The level of PD-L1 on Mo-MDSCs measured as mean fluoresce intensity (MFI) was found to be significantly higher in the group containing al…”
BackgroundMethodDubinski, D., Wölfer, J., Hasselblatt, M., Schneider-Hohendorf, T., Bogdahn, U., Stummer, W., Wiendl, H., & Grauer, O. M. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov280 · Cited by 169
“We detected that both granulocytic and monocytic MDSCs showed an activated phenotype with downregulation of CD16 and upregulation of HLA-DR, which was most prominent in monocytic MDSCs.”
BackgroundInfluentialBlocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy
Xue, S., Hu, M., Iyer, V., & Yu, J. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0455-6 · Cited by 168
“ding directly to the hypoxia response element-4 in the PD-L1 proximal promoter [29] (Fig.”
BackgroundCirculating and Tumor Myeloid-derived Suppressor Cells in Resectable Non–Small Cell Lung Cancer
Yamauchi, Y., Safi, S., Blattner, C., Rathinasamy, A., Umansky, L., Juenger, S., Warth, A., Eichhorn, M., Muley, T., Herth, F. J. F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201708-1707oc · Cited by 168
Messai, Y., Gad, S., Noman, M. Z., Le Teuff, G., Couve, S., Janji, B., Kammerer, S. F., Rioux-Leclerc, N., Hasmim, M., Ferlicot, S., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.11.029 · Cited by 168
Self-citationDaneshmandi, S., Wegiel, B., & Seth, P. (2019) · Cancers · doi:10.3390/cancers11040450 · Cited by 167
“Other studies have also shown that hypoxia mediated through HIF1α regulates expression of PD-L1 [18].”
Chafe, S. C., McDonald, P. C., Saberi, S., Nemirovsky, O., Venkateswaran, G., Burugu, S., Gao, D., Delaidelli, A., Kyle, A. H., Baker, J. H. E., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0657 · Cited by 165
“The hypoxic niche contains numerous nodes of immune suppression, including enhanced expression of PD-L1 on tumor cells (21, 57).”
BackgroundSumimoto, H., Takano, A., Teramoto, K., & Daigo, Y. (2016) · PLOS ONE · doi:10.1371/journal.pone.0166626 · Cited by 165
“This promoter sequence includes potential binding sites for other transcription factors, such as IRF-1 [22], NF-κB [23], STAT-3 [24], and HIF-1α [25].”
BackgroundHoriguchi, H., Loftus, T. J., Hawkins, R. B., Raymond, S. L., Stortz, J. A., Hollen, M. K., Weiss, B. P., Miller, E. S., Bihorac, A., Larson, S. D., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00595 · Cited by 164
Davis, R. J., Van Waes, C., & Allen, C. T. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.05.002 · Cited by 163
“Interestingly, antibody blockade of PD-L1 function following HIF-1α induced overexpression appears to reduce MDSC production of the inflammatory and immunosuppressive cytokines IL-6 and 10, suggesting a link between hypoxia and multiple immunosuppressive mechanisms of MDSCs. Peripheral MDSCs from HNSCC patients also s…”
BackgroundInfluentialTargeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 160
Zhang, P., Miska, J., Lee-Chang, C., Rashidi, A., Panek, W. K., An, S., Zannikou, M., Lopez-Rosas, A., Han, Y., Xiao, T., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1906346116 · Cited by 162
“Emerging evidence indicates that PD-L1 is overexpressed on myeloid lineage in several tumor models (25, 32).”
BackgroundTargeting tumor-associated macrophages as an antitumor strategy
Cheng, N., Bai, X., Shu, Y., Ahmad, O., & Shen, P. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114354 · Cited by 161
Hypoxia‐driven immunosuppression by Treg and type‐2 conventional dendritic cells in HCC
Suthen, S., Lim, C. J., Nguyen, P. H. D., Dutertre, C., Lai, H. L. H., Wasser, M., Chua, C., Lim, T. K. H., Leow, W. Q., Loh, T. J., et al. (2022) · Hepatology · doi:10.1002/hep.32419 · Cited by 161
“[24,25] Hypoxia is also known to up- regulate PD- L1 expression in DCs through hypoxia inducible factor 1 alpha subunit,[36] supporting our current data showing the enrichment of PDL1+ DC subsets in the hypoxic HCC TME.”
MethodMoore, E., Clavijo, P. E., Davis, R., Cash, H., Van Waes, C., Kim, Y., & Allen, C. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0104 · Cited by 157
“It is possible that certain immune cell subsets, such as myeloid-derived suppressor cells or myeloid DCs, dominantly contribute PD-L1 at baseline or in response to IFN (30, 31).”
BackgroundCD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers
Kong, T., Ahn, R., Yang, K., Zhu, X., Fu, Z., Morin, G., Bramley, R., Cliffe, N. C., Xue, Y., Kuasne, H., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1108 · Cited by 175
Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy
Li, J., Eu, J. Q., Kong, L. R., Wang, L., Lim, Y. C., Goh, B. C., & Wong, A. L. A. (2020) · Molecules · doi:10.3390/molecules25204831 · Cited by 159
Immune suppression and reversal of the suppressive tumor microenvironment
Shimizu, K., Iyoda, T., Okada, M., Yamasaki, S., & Fujii, S.-I. (2018) · International Immunology · doi:10.1093/intimm/dxy042 · Cited by 157
Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy
Khan, M., Zhao, Z., Arooj, S., Fu, Y., & Liao, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.587460 · Cited by 158
The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy
Jiang, W., Pan, S., Chen, X., Wang, Z. P., & Zhu, X. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01406-7 · Cited by 174
“In addition, lncRNA HOXA-AS2 significantly promoted proliferation, invasion and migration of NPC cells by upregulating HIF-1α and PD-L1 expression via direct targeting miR-519 [105].”
BackgroundInfluentialTargeting immune checkpoints in breast cancer: an update of early results
Solinas, C., Gombos, A., Latifyan, S., Piccart, M. J., Kok, M., & Buisseret, L. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000255 · Cited by 164
“Poly (ADP-ribose) polymerase (PARP) inhibitors interfere with the mechanisms of DNA repair, increasing DNA damage that in consequence could lead to a higher mutational burden and neoantigen expression, but also to the induction of hypoxia, which has been shown to selectively upregulate the expression of PD-L1 by protu…”
BackgroundZou, M., Liu, W., Li, C., Zheng, D., Zeng, J., Gao, F., Ye, J., & Zhang, X. (2018) · Small · doi:10.1002/smll.201801120 · Cited by 155
Koh, J., Jang, J.-Y., Keam, B., Kim, S., Kim, M.-Y., Go, H., Kim, T. M., Kim, D.-W., Kim, C.-W., Jeon, Y. K., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1108514 · Cited by 152
“Our experiments demonstrated that HIF-1a transcriptionally upregulated PD-L1 by binding to HREs within the PD-L1 promoter region in ALK-translocated lung cancer, similar to murine tumor cells, myeloid-derived suppressor cells, and human breast and prostate cancer cells.(26,27) Moreover, it was demonstrated that EML4-A…”
BackgroundTargeting T Cell Metabolism for Improvement of Cancer Immunotherapy
Le Bourgeois, T., Strauss, L., Aksoylar, H.-I., Daneshmandi, S., Seth, P., Patsoukis, N., & Boussiotis, V. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00237 · Cited by 152
Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression
Awad, R. M., De Vlaeminck, Y., Maebe, J., Goyvaerts, C., & Breckpot, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01977 · Cited by 151
Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors
Kosti, P., Opzoomer, J. W., Larios-Martinez, K. I., Henley-Smith, R., Scudamore, C. L., Okesola, M., Taher, M. Y. M., Davies, D. M., Muliaditan, T., Larcombe-Young, D., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100227 · Cited by 150
Regulatory T cells in immune checkpoint blockade antitumor therapy
Zhang, A., Fan, T., Liu, Y., Yu, G., Li, C., & Jiang, Z. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02156-y · Cited by 188
“Hypoxia is one of the main markers that distinguish solid tumors from normal tissues [181].”
BackgroundRationally Combining Anti-VEGF Therapy with Checkpoint Inhibitors in Hepatocellular Carcinoma
Hato, T., Zhu, A. X., & Duda, D. G. (2016) · Immunotherapy · doi:10.2217/imt.15.126 · Cited by 161
McDonald, P. C., Chafe, S. C., & Dedhar, S. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00027 · Cited by 152
“It was identified recently that hypoxia, through the action of HIF-1α, increases the expression of PD-L1 by tumor cells and by tumor-infiltrating MDSC (Barsoum et al., 2014b; Noman et al., 2014).”
BackgroundCancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Festino, L., Botti, G., Lorigan, P. C., Masucci, G. V., Hipp, J., Horak, C. E., Melero, I., & Ascierto, P. A. (2016) · Drugs · doi:10.1007/s40265-016-0588-x · Cited by 153
“In addition to inflammation, hypoxia operating via hypoxia-inducible factor (HIF)-1a has recently been described to top-regulate PD-L1 expression on both tumor and myeloid cells [32].”
BackgroundBailey, C. M., Liu, Y., Liu, M., Du, X., Devenport, M., Zheng, P., Liu, Y., & Wang, Y. (2022) · Journal of Clinical Investigation · doi:10.1172/jci150846 · Cited by 151
“Targeting HIF-1α in immunotherapy is a relatively new concept, for which proof of principle has been amply demonstrated by others (12, 23, 27).”
Immune Response Regulation in the Tumor Microenvironment by Hypoxia
Labiano, S., Palazón, A., & Melero, I. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.009 · Cited by 169
Mi, Y., Guo, N., Luan, J., Cheng, J., Hu, Z., Jiang, P., Jin, W., & Gao, X. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00737 · Cited by 149
Cysteine Cathepsins in Tumor-Associated Immune Cells
Jakoš, T., Pišlar, A. H., Jewett, A., & Kos, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02037 · Cited by 159
“Furthermore, they express inhibitory ligands, such as PD-L1, that mediate T-cell dysfunction (196).”
BackgroundHypoxia-Driven Effects in Cancer: Characterization, Mechanisms, and Therapeutic Implications
Shi, R., Liao, C., & Zhang, Q. (2021) · Cells · doi:10.3390/cells10030678 · Cited by 145
“HIF-1 upregulates PD-L1 expression in tumors leading to the overstimulation and exhaustion of T cells, blocking their cytotoxic functions [145].”
BackgroundHypoxia: a Double-Edged Sword in Cancer Therapy
Manoochehri Khoshinani, H., Afshar, S., & Najafi, R. (2016) · Cancer Investigation · doi:10.1080/07357907.2016.1245317 · Cited by 147
“Blocking of PD-L1 leads to downregulation of IL-6/IL-10, improvement in T cell function, reduction in immune suppression mediated by dendritic cells, and inhibition of tumor growt (38).”
BackgroundBaxevanis, C. N., Fortis, S. P., & Perez, S. A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.018 · Cited by 167
Hou, A., Hou, K., Huang, Q., Lei, Y., & Chen, W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00783 · Cited by 145
“In tumor site, MDSCs show an increased level of PD-L1 induced by hypoxia and the exposure of splenic MDSC to hypoxia resulted in similar upregulation of PD-L1 (48).”
Role of CD8+ T lymphocyte cells: Interplay with stromal cells in tumor microenvironment
Xie, Q., Ding, J. P., & Chen, Y. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.027 · Cited by 167
Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells
Wang, Z., Till, B., & Gao, Q. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1331807 · Cited by 145
“gamma production of natural killer cells through a cell-contactdependent mechanism that involves membrane-bound transforming growth factor b;(9) (v) induction of immunosuppressive T regulatory cells(10) and (vi) upregulation of programmed death-ligand 1 on MDSC via hypoxia-inducible factor-1a.(11)”
BackgroundMyeloid Cells in Glioblastoma Microenvironment
Leo, A. D., Ugolini, A., & Veglia, F. (2020) · Cells · doi:10.3390/cells10010018 · Cited by 168
Noman, M. Z., Janji, B., Hu, S., Wu, J. C., Martelli, F., Bronte, V., & Chouaib, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0405 · Cited by 143
“Very recently, we demonstrated that hypoxia via HIF1a selectively upregulated PD-L1 onMDSCs (17).”
BackgroundMethodInfluentialSelf-citationYY1 regulates cancer cell immune resistance by modulating PD-L1 expression
Hays, E., & Bonavida, B. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.04.001 · Cited by 149
“, 2015) HIF-1α Up-regulation Transcriptional (Noman et al., 2014)”
Wang, Y., Yu, J., Luo, Z., Shi, Q., Liu, G., Wu, F., Wang, Z., Huang, Y., & Zhou, D. (2021) · Advanced Materials · doi:10.1002/adma.202103497 · Cited by 159
Deletion of Lactate Dehydrogenase-A in Myeloid Cells Triggers Antitumor Immunity
Seth, P., Csizmadia, E., Hedblom, A., Vuerich, M., Xie, H., Li, M., Longhi, M. S., & Wegiel, B. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2938 · Cited by 142
“Hypoxia not only drives the expression of LDH-A, but also other genes such as vascular endothelial growth factor (VEGF), programmed death-ligand 1 (PD-L1) (3), glucose transporter (GLUT1) and many glycolytic enzymes.”
InfluentialZhao, T., Ren, H., Jia, L., Chen, J., Xin, W., Yan, F., Li, J., Wang, X., Gao, S., Qian, D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2948 · Cited by 142
“Recently, it has been proposed that inhibition of HIF-1α could be a complementary approach for cancer immunotherapy [27].”
BackgroundVieira, T., Antoine, M., Hamard, C., Fallet, V., Duruisseaux, M., Rabbe, N., Rodenas, A., Cadranel, J. L., & Wislez, M. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.05.013 · Cited by 148
Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe?
Huang, Y., Lin, D., & Taniguchi, C. M. (2017) · Science China Life Sciences · doi:10.1007/s11427-017-9178-y · Cited by 142
Sormendi, S., & Wielockx, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00040 · Cited by 141
“In addition, HIF-1α-mediated expression of PD-L1 is essential for mediating MDSC immune suppression (as discussed in the previous sections) (184).”
BackgroundPerfluorocarbon regulates the intratumoural environment to enhance hypoxia-based agent efficacy
Wang, W., Cheng, Y., Yu, P., Wang, H., Zhang, Y., Xu, H., Ye, Q., Yuan, A., Hu, Y., & Wu, J. (2019) · Nature Communications · doi:10.1038/s41467-019-09389-2 · Cited by 139
Kordbacheh, T., Honeychurch, J., Blackhall, F. H., Finn, C. F., & Illidge, T. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx790 · Cited by 152
Yuan, Z., Fan, G., Wu, H., Liu, C., Zhan, Y., Qiu, Y., Shou, C., Gao, F., Zhang, J., Yin, P., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.05.017 · Cited by 141
Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment
Gao, Z., Bai, Y., Lin, A., Jiang, A., Zhou, C., Cheng, Q., Liu, Z., Chen, X., Zhang, J., & Luo, P. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01722-0 · Cited by 138
PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3
Ding, L., Chen, X., Xu, X., Qian, Y., Liang, G., Yao, F., Yao, Z., Wu, H., Zhang, J., He, Q., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0071 · Cited by 147
“HIF1a regulates PD-L1 by binding to a hypoxia response element (HRE) in the PD-L1 promoter to activate PD-L1 transcription (19).”
BackgroundCao, D., Qi, Z., Pang, Y., Li, H., Xie, H., Wu, J., Huang, Y., Zhu, Y., Shen, Y., Zhu, Y., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3842 · Cited by 138
Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy
Joshi, S., & Sharabi, A. B. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108114 · Cited by 154
“In the hepatocellular carcinoma model, hypoxia promotes stabilization of HIF1α which induces increased expression of ectoenzyme, ectonucleoside triphosphate diphosphohydrolase 2 (ENTPD2/CD39L1) in cancer cells (Chiu et al., 2017).”
BackgroundInfluentialImmune regulatory network in successful pregnancy and reproductive failures
Ghaebi, M., Nouri, M., Ghasemzadeh, A., Farzadi, L., Jadidi‐Niaragh, F., Ahmadi, M., & Yousefi, M. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.01.016 · Cited by 143
Hossain, M. A., Liu, G., Dai, B., Si, Y., Yang, Q., Wazir, J., Birnbaumer, L., & Yang, Y. (2020) · Medicinal Research Reviews · doi:10.1002/med.21727 · Cited by 154
“I molecules on tumor cells and decreases their immunogenicity.21 The accumulation of extracellular adenosine under hypoxic condition strongly suppresses CD8+ CTL function through interaction with its receptor A2AR on CD8+ CTLs.88,89 Importantly, HIF‐1α has been reported to drive immunosuppression by directly regulatin…”
BackgroundYaseen, M. M., Abuharfeil, N. M., Darmani, H., & Daoud, A. K. (2020) · Open Biology · doi:10.1098/rsob.200111 · Cited by 151
Fleming, V., Hu, X., Weller, C., Weber, R., Groth, C., Riester, Z., Hüser, L., Sun, Q., Nagibin, V. S., Kirschning, C. J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0053 · Cited by 145
Self-citationBigos, K. J. A., Quiles, C. G., Lunj, S., Smith, D. J., Krause, M., Troost, E. G. C., West, C., Hoskin, P., & Choudhury, A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1331355 · Cited by 166
Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy
Liu, H., Zhao, Z., Zhang, L., Li, Y., Jain, A., Barve, A. J., Jin, W., Liu, Y., Fetse, J., & Cheng, K. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0705-y · Cited by 137
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target
Qian, W., Zhao, M., Wang, R., & Li, H. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01161-8 · Cited by 144
Role of hypoxia in the tumor microenvironment and targeted therapy
Chen, G., Wu, K., Li, H., Xia, D., & He, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.961637 · Cited by 346
Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
Shen, X., Zhang, L., Li, J., Li, Y., Wang, Y., & Xu, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01337 · Cited by 139
“Hypoxia markedly induces the expression of PD-L1 on the surface of myeloid-derived suppressor cells (MDSCs), macrophages, DCs, monocytes, and tumor cells (201, 203, 204).”
BackgroundInfluentialAnti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α
Tezera, L. B., Bielecka, M. K., Ogongo, P., Walker, N. F., Ellis, M. J., Garay‐Baquero, D. J., Thomas, K., Reichmann, M. T., Johnston, D. A., Wilkinson, K. A., et al. (2020) · eLife · doi:10.7554/elife.52668 · Cited by 147
Immunological Microenvironment of Hepatocellular Carcinoma and Its Clinical Implication
Nishida, N., & Kudo, M. (2017) · Oncology · doi:10.1159/000451015 · Cited by 131
T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints
Mirzaei, R., Sarkar, S., & Yong, V. W. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.11.005 · Cited by 147
Xu, W., Hiếu, T., Malarkannan, S., & Wang, L. L. (2018) · Cellular and Molecular Immunology · doi:10.1038/cmi.2017.148 · Cited by 144
Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade
Fortin, B. M., Pfeiffer, S. M., Insua‐Rodríguez, J., Alshetaiwi, H. S., Moshensky, A., Song, W. A., Mahieu, A. L., Chun, S. K., Lewis, A. N., Hsu, A., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01859-0 · Cited by 157
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
Buqué, A., Bloy, N., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Fridman, W. H., Fucikova, J., Galon, J., Marabelle, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008814 · Cited by 129
Adoptive CD8+ T cell therapy against cancer:Challenges and opportunities
Jiang, X., Jiang, X., Liu, M., Xing, H., Wang, Z., Huang, L., Mellor, A. L., Wang, W., & Wu, S. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.07.017 · Cited by 141
Augustin, R. C., Delgoffe, G. M., & Najjar, Y. G. (2020) · Cancers · doi:10.3390/cancers12123802 · Cited by 129
“Hypoxic conditions have been shown to further stimulate the immunosuppressive function of these cells; MDSC PD-L1 expression is also strongly upregulated in response to HIF-1α [28].”
BackgroundFu, Z., Mowday, A. M., Smaill, J. B., Hermans, I. F., & Patterson, A. V. (2021) · Cells · doi:10.3390/cells10051006 · Cited by 147
“HIF-1 directly regulates the expression of PD-L1, and under hypoxic conditions, PD-L1 is upregulated on MDSCs to promote T-cell anergy and tolerance [74,98].”
BackgroundYong, T., Wei, Z., Gan, L., & Yang, X. (2022) · Advanced Materials · doi:10.1002/adma.202201054 · Cited by 130
Metadata
- Authors
- Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S.
- Affiliations
- Inserm (FR)
- Istituto Oncologico Veneto (IT)
- Centre de Recherche Public de la Santé (LU)
- Institut Gustave Roussy (FR)
- University of Verona (IT)
- Unité Institut National de la Santé et de la Recherche Médicale U753, Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France 1
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2014-04-28
- Volume
- 211
- Issue
- 5
- Pages
- 781-790
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4010891
- OpenAlex
- W2149360266
- Semantic Scholar
- dad078dcb463c50f1571acb3306b01954a153c29
- Cited by
- 2,166
- References
- 24
- Citations by year
- 2026: 171 · 2025: 187 · 2024: 208 · 2023: 219 · 2022: 239 · 2021: 331 · 2020: 224 · 2019: 147 · 2018: 139 · 2017: 120 · 2016: 101 · 2015: 61 · 2014: 18
- FWCI
- 48.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-L1, HIF-1α, hypoxia, myeloid-derived suppressor cells, tumor microenvironment, immune checkpoint blockade, T cell activation, hypoxia response element, IL-10, interleukin-6, tumor-associated macrophages, cancer immunotherapy, CTLA-4, PD-1 ligands
- MeSH terms
- Animals, Diamines, Enzyme-Linked Immunosorbent Assay, Female, Flow Cytometry, Gene Expression Regulation, Luciferases, Lymphocyte Activation, Mice, Inbred C57BL, Organic Chemicals, Quinolines, T-Lymphocytes, Cell Hypoxia, Myeloid Cells, RNA Interference, Chromatin Immunoprecipitation, Mice, Hypoxia-Inducible Factor 1, alpha Subunit, Benzothiazoles, Tumor Microenvironment, Real-Time Polymerase Chain Reaction, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.